BLTE
Belite Bio, Inc NASDAQ Listed Apr 29, 2022$156.00
Mkt Cap $6.2B
52w Low $56.10
69.4% of range
52w High $200.00
50d MA $165.85
200d MA $126.57
P/E (TTM)
-67.0x
EV/EBITDA
-59.5x
P/B
6.7x
Debt/Equity
0.0x
ROE
-10.1%
P/FCF
-144.3x
RSI (14)
—
ATR (14)
—
Beta
-1.22
50d MA
$165.85
200d MA
$126.57
Avg Volume
174.0K
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
5820 Oberlin Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | AMC | -0.56 | -0.38 | +32.1% | 177.58 | +0.0% | -5.5% | +0.1% | -2.8% | -2.4% | +0.9% | — |
| Nov 10, 2025 | AMC | -0.53 | -0.65 | -22.6% | 117.34 | -2.0% | -9.9% | -5.6% | -4.2% | -0.5% | -0.4% | — |
| Aug 11, 2025 | AMC | -0.47 | -0.50 | -6.4% | 69.50 | +0.0% | +4.6% | +3.0% | -0.7% | -4.1% | -6.5% | — |
| May 13, 2025 | AMC | -0.36 | -0.45 | -25.0% | 60.89 | +0.0% | +1.2% | +10.1% | +5.8% | +6.7% | +6.4% | — |
| Mar 17, 2025 | AMC | -0.30 | -0.32 | -6.7% | 67.81 | +0.3% | +0.8% | -0.2% | -0.1% | -0.8% | -1.3% | — |
| Nov 12, 2024 | AMC | -0.30 | -0.28 | +6.7% | 81.15 | +0.1% | +1.3% | +3.1% | +2.0% | +2.0% | +1.5% | — |
| Aug 9, 2024 | AMC | -0.28 | -0.31 | -10.7% | 49.48 | -4.3% | -1.9% | +1.8% | +0.8% | +0.8% | +0.9% | — |
| May 13, 2024 | AMC | -0.34 | -0.27 | +20.6% | 41.69 | -0.8% | +0.7% | +1.8% | +1.7% | +7.9% | +8.3% | — |
| Mar 11, 2024 | AMC | -0.36 | -0.25 | +30.6% | 44.60 | +1.1% | -12.5% | -14.8% | -15.2% | -13.7% | -8.1% | — |
| Nov 13, 2023 | AMC | -0.31 | -0.40 | -29.0% | 39.30 | -2.0% | -3.6% | -5.8% | -5.4% | -5.3% | -2.7% | — |
| Aug 8, 2023 | AMC | -0.24 | -0.26 | -8.3% | 22.54 | +0.9% | +2.3% | +8.7% | +4.2% | +2.5% | -1.6% | — |
| May 10, 2023 | AMC | -0.20 | -0.33 | -65.0% | 26.22 | +2.6% | +2.3% | -2.6% | -10.4% | -13.2% | -14.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $165.23 | $168.90 | +2.2% | +1.3% | -0.5% | -2.4% | -1.3% | -3.9% |
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $172.76 | $176.18 | +2.0% | +0.2% | -0.5% | -2.3% | -8.5% | -4.2% |
| Mar 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $177.58 | $177.60 | +0.0% | -5.5% | +0.1% | -2.8% | -2.4% | +0.9% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $177.58 | $177.60 | +0.0% | -5.5% | +0.1% | -2.8% | -2.4% | +0.9% |
| Mar 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $177.58 | $177.60 | +0.0% | -5.5% | +0.1% | -2.8% | -2.4% | +0.9% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $167.34 | $167.09 | -0.1% | -1.0% | +1.0% | +1.0% | +3.6% | +11.9% |
| Dec 2 | Mizuho | Upgrade | Neutral → Outperform | — | $154.02 | $160.43 | +4.2% | -2.1% | -1.4% | -1.8% | -2.6% | -2.7% |
| Dec 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $137.44 | $153.50 | +11.7% | +12.1% | +9.7% | +10.4% | +10.1% | +9.1% |
| Oct 31 | Benchmark | Maintains | Buy → Buy | — | $98.10 | $98.85 | +0.8% | +8.0% | +14.6% | +13.2% | +14.6% | +13.9% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.48 | $69.60 | +0.2% | -3.9% | -3.7% | +5.1% | +5.4% | +1.0% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.81 | $57.99 | +2.1% | +4.7% | +3.2% | +5.8% | +12.9% | +9.2% |
| May 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $61.60 | $62.50 | +1.5% | +8.9% | +4.5% | +5.5% | +5.2% | +9.2% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.60 | $62.50 | +1.5% | +8.9% | +4.5% | +5.5% | +5.2% | +9.2% |
| Mar 26 | Benchmark | Maintains | Buy → Buy | — | $64.50 | $66.58 | +3.2% | +1.1% | +3.6% | +3.4% | +2.7% | +0.8% |
| Mar 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $67.81 | $68.03 | +0.3% | +0.8% | -0.2% | -0.1% | -0.8% | -1.3% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.81 | $68.03 | +0.3% | +0.8% | -0.2% | -0.1% | -0.8% | -1.3% |
| Jan 21 | Benchmark | Maintains | Buy → Buy | — | $56.21 | $58.24 | +3.6% | +3.6% | +4.8% | +3.5% | +5.7% | +2.0% |
| Nov 15 | Maxim Group | Maintains | Buy → Buy | — | $83.66 | $83.60 | -0.1% | -1.0% | -1.1% | -1.6% | -1.4% | -1.4% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $81.15 | $81.20 | +0.1% | +1.3% | +3.1% | +2.0% | +2.0% | +1.5% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.69 | $48.67 | -0.0% | +0.0% | +0.3% | +0.2% | -0.3% | -0.8% |
| Aug 13 | Benchmark | Maintains | Buy → Buy | — | $48.55 | $49.04 | +1.0% | +3.7% | +2.8% | +2.8% | +2.9% | +2.8% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.55 | $49.04 | +1.0% | +3.7% | +2.8% | +2.8% | +2.9% | +2.8% |
| Jun 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.98 | $49.80 | -0.4% | +0.2% | -0.0% | -0.8% | -0.7% | -2.1% |
| May 16 | Benchmark | Maintains | Buy → Buy | — | $42.45 | $42.42 | -0.1% | -0.2% | +5.9% | +6.4% | +7.0% | +6.1% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.00 | $42.00 | +0.0% | +1.1% | +0.9% | +7.1% | +7.5% | +8.1% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.77 | $43.26 | -1.2% | +0.4% | -0.0% | -0.7% | -8.8% | -12.3% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.04 | $38.01 | -2.6% | -2.6% | -3.2% | -1.5% | +4.9% | +14.2% |
| Dec 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.89 | $45.50 | -0.8% | +0.3% | -0.0% | -0.3% | -6.8% | -14.8% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.88 | $37.50 | -1.0% | -2.3% | -1.8% | -1.8% | +0.9% | -0.2% |
| Nov 7 | Benchmark | Maintains | Buy → Buy | — | $39.23 | $39.00 | -0.6% | +2.2% | -1.4% | -0.6% | +0.3% | +0.2% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.03 | $39.20 | +0.4% | +0.5% | +2.7% | -0.9% | -0.1% | +0.8% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.06 | $22.90 | -0.7% | +6.2% | +1.8% | +0.2% | -3.9% | -3.8% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.20 | $18.00 | -1.1% | -1.6% | +2.3% | +12.9% | +32.4% | +27.6% |
| Jul 25 | Benchmark | Maintains | Buy → Buy | — | $18.20 | $18.00 | -1.1% | -1.6% | +2.3% | +12.9% | +32.4% | +27.6% |
| Jun 20 | Benchmark | Maintains | Buy → Buy | — | $13.23 | $13.23 | +0.0% | +6.9% | +2.8% | -7.3% | -15.5% | +1.1% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.15 | $17.14 | -0.1% | -9.6% | -12.0% | -11.7% | -13.7% | -12.4% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.51 | $28.70 | +0.7% | +5.2% | +2.2% | +0.5% | +1.7% | +2.9% |
| Apr 4 | Benchmark | Maintains | Buy → Buy | — | $28.51 | $28.70 | +0.7% | +5.2% | +2.2% | +0.5% | +1.7% | +2.9% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.27 | $32.31 | -2.9% | -1.1% | +0.6% | -4.3% | -3.5% | -0.5% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.56 | $32.12 | +1.8% | +5.4% | +4.2% | +6.0% | +0.9% | +1.7% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.60 | $35.13 | +4.6% | +0.0% | -0.3% | -10.7% | -12.2% | -9.6% |
| Jul 1 | Benchmark | Maintains | Buy → Buy | — | $31.14 | $32.00 | +2.8% | +21.0% | +41.3% | +32.0% | +33.4% | +38.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 100 | $155.97 | $16K | 766 | -0.72% | — |
| May 6, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 240 | $154.41 | $37K | 866 | -0.72% | — |
| May 6, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 128 | $153.42 | $20K | 1,106 | -0.72% | — |
| May 6, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 424 | $152.67 | $65K | 1,234 | -0.72% | — |
| May 6, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 8 | $151.57 | $1K | 1,658 | -0.72% | — |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 68 | $158.11 | $11K | 1,666 | -0.13% | — |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 155 | $157.29 | $24K | 1,734 | -0.13% | — |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 121 | $156.53 | $19K | 1,889 | -0.13% | — |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 173 | $155.48 | $27K | 2,010 | -0.13% | — |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 363 | $154.44 | $56K | 2,183 | -0.13% | — |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 120 | $153.92 | $18K | 2,546 | -0.13% | — |
| May 4, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 172 | $157.49 | $27K | 2,666 | +1.19% | — |
| May 4, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 235 | $156.57 | $37K | 2,838 | +1.19% | — |
| May 4, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 325 | $155.21 | $50K | 3,073 | +1.19% | — |
| May 4, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 236 | $154.24 | $36K | 3,398 | +1.19% | — |
| May 4, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 32 | $153.50 | $5K | 3,634 | +1.19% | — |
| May 1, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 23 | $160.00 | $4K | 3,666 | -0.08% | — |
| May 1, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 38 | $159.08 | $6K | 3,689 | -0.08% | — |
| May 1, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 65 | $158.35 | $10K | 3,727 | -0.08% | — |
| May 1, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 106 | $157.45 | $17K | 3,792 | -0.08% | — |
| May 1, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 82 | $156.24 | $13K | 3,898 | -0.08% | — |
| May 1, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 346 | $155.48 | $54K | 3,980 | -0.08% | — |
| May 1, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 288 | $154.38 | $44K | 4,326 | -0.08% | — |
| May 1, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 52 | $153.89 | $8K | 4,614 | -0.08% | — |
| Apr 30, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 101 | $158.15 | $16K | 4,666 | -0.22% | +0.02% |
| Apr 30, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 340 | $157.37 | $54K | 4,767 | -0.22% | +0.02% |
| Apr 30, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 517 | $156.59 | $81K | 5,107 | -0.22% | +0.02% |
| Apr 30, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 42 | $155.68 | $7K | 5,624 | -0.22% | +0.02% |
| Apr 29, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 22 | $158.19 | $3K | 5,666 | -2.71% | -1.99% |
| Apr 29, 2026 | MATA NATHAN L. | Chief Scientific Officer | Sell | 102 | $157.39 | $16K | 5,688 | -2.71% | -1.99% |
No recent filings available.
Data updated apr 26, 2026 9:54am
· Source: massive.com